Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Moderate Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $204.64.

Several research firms recently issued reports on ASND. Evercore ISI increased their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company.

Ascendis Pharma A/S Trading Up 1.2 %

Shares of NASDAQ ASND opened at $167.99 on Tuesday. The firm has a market cap of $10.20 billion, a P/E ratio of -23.66 and a beta of 0.62. The business’s 50 day moving average is $142.05 and its 200-day moving average is $136.15. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Advisors Asset Management Inc. raised its holdings in shares of Ascendis Pharma A/S by 23.2% in the third quarter. Advisors Asset Management Inc. now owns 4,742 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 894 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in Ascendis Pharma A/S by 35.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after acquiring an additional 48,120 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Ascendis Pharma A/S by 49.5% during the third quarter. The Manufacturers Life Insurance Company now owns 71,307 shares of the biotechnology company’s stock worth $10,647,000 after purchasing an additional 23,595 shares during the period. Finepoint Capital LP boosted its holdings in shares of Ascendis Pharma A/S by 0.4% in the 3rd quarter. Finepoint Capital LP now owns 190,072 shares of the biotechnology company’s stock valued at $28,380,000 after acquiring an additional 800 shares during the last quarter. Finally, Acuta Capital Partners LLC purchased a new stake in Ascendis Pharma A/S in the third quarter valued at $3,136,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.